MEK162 (Binimetinib, ARRY-162)

MEK162 (Binimetinib, ARRY-162) is an inhibitor of MEK and MEK1 used in studies of MAPK / ERK Signaling and Apoptosis and related signaling programs. In practice, this places the compound in experiments that measure mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and caspase-associated cell-death signaling and survival decisions in apoptosis, autophagy, and cancer models.

By inhibiting MEK and MEK1, MEK162 (Binimetinib, ARRY-162) can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and caspase-associated cell-death signaling and survival decisions. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, autophagy, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving MEK and MEK1
• Pathway perturbation studies connected to MAPK / ERK Signaling and Apoptosis and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, MEK162 (Binimetinib, ARRY-162) is appropriate when a defined chemical perturbant is needed to connect MEK and MEK1 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, autophagy, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.